Renal, hematologic and infectious complications in multiple myeloma

被引:58
作者
Bladé, J [1 ]
Rosiñol, L [1 ]
机构
[1] Hosp Clin Barcelona, IDIBAPS,Postgrad Sch Hematol Farreras Valenti, Inst Hematol & Oncol, Dept Hematol, Barcelona, Spain
关键词
multiple myeloma; renal failure; anemia; erythropoietin; infection;
D O I
10.1016/j.beha.2005.01.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal failure is a common complication in patients with multiple myeloma. It is generally due to tubular light-chain damage, and it is reversible in about 50% of patients. The reversibility rate depends on the degree of light-chain nephropathy. The initial therapy should consist of dexamethasome- or cyclophosphamide-based regimens. High-dose therapy/autologous transplant may be of benefit in selected patients. Early plasma exchange may be useful in patients who have severe renal failure but do not yet require dialysis. Renal replacement with dialysis is a worthwhile measure in patients with end-stage renal failure. Anemia is the most common hematologic complication. About 70% of anemic patients respond to recombinant human erythropoietin (rHuEPO), resulting not only in an increase in the hemoglobin level but also in an improvement in the quality of life. The hemoglobin level should ideally be maintained at around 12 g/dL. Infection is the main cause of morbidity and mortality in patients with myeloma. The highest risk of infection is within the first 2 months of initiation of therapy as well as in patients with renal failure and in those with relapsed and refractory disease.
引用
收藏
页码:635 / 652
页数:18
相关论文
共 91 条
[71]  
POZZI C, 1987, CLIN NEPHROL, V28, P1
[72]   MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE (RANDALL TYPE) - RELATIONSHIP WITH STRUCTURAL ABNORMALITIES OF IMMUNOGLOBULIN-CHAINS [J].
PREUDHOMME, JL ;
AUCOUTURIER, P ;
TOUCHARD, G ;
STRIKER, L ;
KHAMLICHI, AA ;
ROCCA, A ;
DENOROY, L ;
COGNE, M .
KIDNEY INTERNATIONAL, 1994, 46 (04) :965-972
[73]   MANIFESTATIONS OF SYSTEMIC LIGHT CHAIN DEPOSITION [J].
RANDALL, RE ;
WILLIAMSON, WC ;
MULLINAX, F ;
TUNG, MY ;
STILL, WJS .
AMERICAN JOURNAL OF MEDICINE, 1976, 60 (02) :293-299
[74]   A phase 2 study of bortezomib in relapsed, refractory myeloma [J].
Richardson, PG ;
Barlogie, B ;
Berenson, J ;
Singhal, S ;
Jagannath, S ;
Irwin, D ;
Rajkumar, SV ;
Srkalovic, G ;
Alsina, M ;
Alexanian, R ;
Siegel, D ;
Orlowski, RZ ;
Kuter, D ;
Limentani, SA ;
Lee, S ;
Hideshima, T ;
Esseltine, DL ;
Kauffman, M ;
Adams, J ;
Schenkein, DP ;
Anderson, KC .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) :2609-2617
[75]   Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology [J].
Rizzo, JD ;
Lichtin, AE ;
Woolf, SH ;
Seidenfeld, J ;
Bennett, CL ;
Cella, D ;
Djulbegovic, B ;
Goode, MJ ;
Jakubowski, AA ;
Lee, SJ ;
Miller, CB ;
Rarick, MU ;
Regan, DH ;
Browman, GP ;
Gordon, MS .
BLOOD, 2002, 100 (07) :2303-2320
[76]   Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology [J].
Rizzo, JD ;
Lichtin, AE ;
Woolf, SH ;
Seidenfeld, J ;
Bennett, CL ;
Cella, D ;
Djulbegovic, B ;
Goode, MJ ;
Jakubowski, AA ;
Lee, SJ ;
Miller, CB ;
Rarick, MU ;
Regan, DH ;
Browman, GP ;
Gordon, MS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) :4083-4107
[77]   SIMULTANEOUS OCCURRENCE OF MULTIPLE-MYELOMA AND ACUTE MYELOBLASTIC-LEUKEMIA - FACT OR MYTH [J].
ROSNER, F ;
GRUNWALD, HW .
AMERICAN JOURNAL OF MEDICINE, 1984, 76 (05) :891-899
[78]   MULTIPLE-MYELOMA AND SEVERE RENAL-FAILURE - A CLINICOPATHOLOGICAL STUDY OF OUTCOME AND PROGNOSIS IN 34 PATIENTS [J].
ROTA, S ;
MOUGENOT, B ;
BAUDOUIN, B ;
DEMEYERBRASSEUR, M ;
LEMAITRE, V ;
MICHEL, C ;
MIGNON, F ;
RONDEAU, E ;
VANHILLE, P ;
VERROUST, P ;
RONCO, P .
MEDICINE, 1987, 66 (02) :126-137
[79]  
San Miguel J F, 2000, Hematol J, V1, P28
[80]  
SANDERS PW, 1994, J LAB CLIN MED, V124, P484